News
MNOV
2.170
+0.46%
0.010
Weekly Report: what happened at MNOV last week (1209-1213)?
Weekly Report · 5d ago
Weekly Report: what happened at MNOV last week (1202-1206)?
Weekly Report · 12/09 10:37
MediciNova Price Target Maintained With a $9.00/Share by D. Boral Capital
Dow Jones · 12/06 12:19
MediciNova Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/06 12:19
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
Benzinga · 12/06 12:09
MediciNova, Inc. Announces Interim Analysis Results from COMBAT-ALS Trial of MN-166 at International Symposium on ALS/MND
Barchart · 12/06 03:14
MediciNova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of MN-166 In ALS At The 35th International Symposium On ALS/MND
Benzinga · 12/05 23:04
MEDICINOVA INC - POSITIVE CORRELATIONS OBSERVED BETWEEN 6-MONTH AND 12-MONTH DATA
Reuters · 12/05 23:00
MEDICINOVA INC - EXPECTS TO COMPLETE PATIENT ASSIGNMENTS BY JUNE 2025 WITH TRIAL RESULTS EXPECTED IN 2026
Reuters · 12/05 23:00
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 12/02 13:56
MediciNova Price Target Announced at $9.00/Share by D. Boral Capital
Dow Jones · 12/02 13:40
D. Boral Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $9
Benzinga · 12/02 13:30
MediciNova initiated with a Buy at D. Boral Capital
TipRanks · 12/02 12:26
Weekly Report: what happened at MNOV last week (1125-1129)?
Weekly Report · 12/02 10:38
Weekly Report: what happened at MNOV last week (1118-1122)?
Weekly Report · 11/25 10:32
MediciNova, Inc. Provides Corporate Update and Highlights Ongoing Clinical Trials for MN166 and Other Programs
Barchart · 11/19 18:24
MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency
Benzinga · 11/19 14:17
MediciNova provides update in letter to stockholders
TipRanks · 11/19 14:15
MEDICINOVA CEO YUICHI IWAKI PROVIDES CORPORATE UPDATE IN LETTER TO STOCKHOLDERS
Reuters · 11/19 14:00
More
Webull provides a variety of real-time MNOV stock news. You can receive the latest news about Medicinova through multiple platforms. This information may help you make smarter investment decisions.
About MNOV
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.